financetom
Business
financetom
/
Business
/
Cognex Q2 Adjusted EPS, Revenue Decline; Q3 Sales Outlook Set -- Shares Slide After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cognex Q2 Adjusted EPS, Revenue Decline; Q3 Sales Outlook Set -- Shares Slide After Hours
Jul 31, 2024 3:21 PM

05:49 PM EDT, 07/31/2024 (MT Newswires) -- Cognex ( CGNX ) reported Q2 adjusted earnings late Wednesday of $0.23 per diluted share, down from $0.33 a year earlier.

Analysts polled by Capital IQ expected $0.21.

Revenue for the quarter that ended June 30 was $239.3 million, down from $242.5 million a year earlier.

Analysts surveyed by Capital IQ expected $239.9 million.

The company expects Q3 revenue to be between $225 million and $240 million. Analysts polled by Capital IQ expect $243.5 million.

Shares of Cognex ( CGNX ) were trading 6.5% lower in after-hours activity.

Price: 46.38, Change: -3.24, Percent Change: -6.53

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Blank Check Co Launchpad Streetlight Acquisition Corp Files For IPO Of Up To $200 Million - SEC Filing
BRIEF-Blank Check Co Launchpad Streetlight Acquisition Corp Files For IPO Of Up To $200 Million - SEC Filing
Nov 7, 2025
* BLANK CHECK CO LAUNCHPAD STREETLIGHT ACQUISITION CORP FILES FOR IPO OF UP TO $200 MILLION - SEC FILING * LAUNCHPAD STREETLIGHT ACQUISITION CORP SAYS CANTOR IS UNDERWRITER TO IPO * LAUNCHPAD STREETLIGHT ACQUISITION CORP TO LIST ON NASDAQ UNDER SYMBOL LPSLU Source text: Further company coverage: [ ] ...
Ionis Pharmaceuticals Insider Sold Shares Worth $2,621,816, According to a Recent SEC Filing
Ionis Pharmaceuticals Insider Sold Shares Worth $2,621,816, According to a Recent SEC Filing
Nov 7, 2025
05:21 PM EST, 11/07/2025 (MT Newswires) -- Richard S Geary, Executive Vice President, Chief Development Officer, on November 05, 2025, sold 34,639 shares in Ionis Pharmaceuticals ( IONS ) for $2,621,816. Following the Form 4 filing with the SEC, Geary has control over a total of 59,657 common shares of the company, with 59,657 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/874015/000087401525000277/xslF345X05/edgardoc.xml...
Alphabet Insider Sold Shares Worth $9,212,980, According to a Recent SEC Filing
Alphabet Insider Sold Shares Worth $9,212,980, According to a Recent SEC Filing
Nov 7, 2025
05:20 PM EST, 11/07/2025 (MT Newswires) -- Sundar Pichai, Director, Chief Executive Officer, on November 05, 2025, sold 32,500 shares in Alphabet (GOOGL) for $9,212,980. Following the Form 4 filing with the SEC, Pichai has control over a total of 2,337,119 Class C capital shares, 227,560 Class A common shares and 74,874 Class C Google stock units, all held directly....
Ionis Pharmaceuticals Insider Sold Shares Worth $609,379, According to a Recent SEC Filing
Ionis Pharmaceuticals Insider Sold Shares Worth $609,379, According to a Recent SEC Filing
Nov 7, 2025
05:21 PM EST, 11/07/2025 (MT Newswires) -- Brian Birchler, Executive Vice President, Corporate and Development Operations, on November 06, 2025, sold 8,000 shares in Ionis Pharmaceuticals ( IONS ) for $609,379. Following the Form 4 filing with the SEC, Birchler has control over a total of 48,826 common shares of the company, with 48,826 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/874015/000087401525000278/xslF345X05/edgardoc.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved